Clinical Trial Update: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT [Phase 1]

View source ↗

Summary

Stanford is conducting a Phase 1 study evaluating cessation of tacrolimus immunosuppression after allogeneic hematopoietic cell transplantation to manage graft-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Graft-versus-host Disease
• Myelodysplastic Syndrome
• Myelofibrosis
• Myelomonocytic Leukemia

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Stanford University | Conditions: GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Status: NOT_YET_RECRUITING